Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).
Pioglitazone for Oral Premalignant Lesions
(Posted: 04/20/2010) - In this trial, patients with oral leukoplakia will be randomly assigned to receive either pioglitazone or placebo pills daily for 6 months.
Adjuvant Breast Cancer Therapy for Premenopausal Women
(Posted: 10/11/2005, Updated: 04/08/2010) - In this trial, researchers will study three treatment groups of premenopausal women with endocrine-responsive breast cancer to see which treatment regimen provides the greatest benefits for this population.
New Chemotherapy Drug for Advanced Cervical Cancer
(Posted: 04/06/2010) - In this clinical trial, women with cervical cancer that has recurred or demonstrated resistance to previous chemotherapy and that cannot be treated surgically will be treated with the drug ixabepilone.
Vaccine Therapy for Patients with Progressive Stage D0 Prostate Cancer
(Posted: 03/23/2010) - In this phase I trial, researchers are evaluating the safety of a vaccine to treat stage D0 prostate cancer and whether the body’s immune system will respond to it by producing T lymphocytes that will selectively attack cancer cells.